Current prevailing knowledge on EMT (epithelial mesenchymal transition) deems epithelial cells acquire the characters of mesenchymal cells to be capable of invading and metastasizing on their own.
Introduction
The prevailing concept for the metastasis of mesenchymal-like cancer cells is that they have undergone the EMT (epithelial-mesenchymal transition) process and hence have acquired the mesenchymal cell characteristics of being able to invade by themselves [1] [2] [3] . This is evidenced by the synergistic orchestra between the EMT-TFs (EMT-activating transcription factors) signaling network and the cell migration/invasion signaling networks including integrins, MMPs (metalloproteinases), RTKs (Receptor tyrosine kinases) and small GTPases 4, 5 . EMT has also been suggested to promote primary tumor growth and progression by linking the EMT-TFs signaling to multiple growth factor signalings and cell division signaling in the cancer cells. However controversially, a partial EMT process with adaptive plasticity to the homing microenvironment and/or a complete reversal of EMT process called MET (mesenchymal-epithelial transition) might be involved or even required for successful homing and growth of some types of cancer in vivo [6] [7] [8] . Till today, the critical role of EMT in cancer in vivo is still actively debated 3 .
In recent years, cancer-associated fibroblasts (CAFs) have been suggested to not only support cancer growth 9, 10 and contribute to the inflammation in the tumor microenvironment [11] [12] [13] , but also to play an important role in local cancer invasion and cancer distal metastasis [14] [15] [16] . For epithelial-like cancer cells, it is relatively straightforward to understand that they follow fibroblasts created micro-tunnels to invade through 3-D matrices 17, 18 since epithelial-like cancer cells are usually not capable by themselves of invading through a dense 3-D microenvironment filled with extracellular matrices. However, for mesenchymal-like cancer cells, the story becomes much more complicated. In a solid tumor microenvironment, with both mesenchymal-like cancer cells and fibroblasts which can invade through 3-D matrices by themselves, a simple question to ask would be whether fibroblasts are facilitating or dampening the mesenchymal cancer cell invasion.
With the above question left to be answered in detail, recent studies on the co-invasion of these two mesenchymal cell types in the same 3-D microenvironment have reported that fibroblasts facilitate cancer cell invasion 19, 20 and a direct contact between human lung cancer cells and fibroblasts is essential during their co-invasion through 3-D matrices, however the detailed mechanisms are largely unknown 21 .
Cadherin-11, also called OB-cadherin, a type II classical cadherin, was initially discovered in osteoblasts 22 . In the past twenty years, the Brenner lab and peers have observed that cadherin-11 is also specifically expressed in fibroblasts from various tissues [23] [24] [25] [26] . It has also been reported that there is a strong positive correlation between the protein expression level of cadherin-11 in breast cancer cells and the severity of their metastasis in vivo 27 . The cadherin expression switch from E-cadherin to cadherin-11 in cancer cells has also been defined as one of the major cancer EMT markers 28, 29 . Cadherins regulate homophilic cell-to-cell adhesion, which has been classically defined as one type of cadherin binds to the same type of cadherin on the other cell in trans 30, 31 . Such cadherin adherens junction (AJ) formation happens generally in the same cell types. Interestingly, in a solid tumor microenvironment, there are cadherin-11 expressions in both mesenchymal-like cancer cells and stromal fibroblasts. Thus, it is the homophilic adhesion at the molecular level (cadherin-11 to cadherin-11), but heterophilic adhesion at the cellular level (cancer cells to fibroblasts). Hence, in this study, we focused on the critical post EMT events happening after the cadherin switch from E-cadherin to cadherin-11 in cancer cells. We scrutinized the role of cadherin-11 dependent cancer-to-fibroblast adhesion in multiple 3D ex vivo cell co-invasion models. We then determined the correlation and clinical relevance of cadherin-11 mediated cancer hijacking fibroblasts in human breast cancer progression by employing most up-to-date bioinformatics databases. We further studied how such cadherin-11 mediated cancer hijacking fibroblasts post EMT events contribute to cancer growth, local invasion, distant metastasis, progression and immune rejection against tumor implants in multiple mouse models in vivo.
Results

Cadherin-11 positive cancer cells form adherens junctions (AJs) with fibroblasts
The adherens junction has been defined as a cell-cell junction where the cadherins on one cell bind to the same type of cadherins on the other cell (homophilic binding). Hence, it has been largely studied in cultures of a single cell type 30, 31 . Adherens junction formation also requires a whole set of intracellular AJ structural proteins, such as catenins, to stabilize such cell-to-cell cadherin binding. It is not known if the cancer cells that express cadherin-11 have enough molecular machinery to be capable of forming stable AJs with fibroblasts that endogenously express abundant cadherin-11 proteins 26, 32 . To address this question, we first cocultured MDA-MB-231 or BT549 breast cancer cells, which inherently express cadherin-11 proteins 27 , with primary human fibroblasts and stained for cadherin-11 protein.
The results confirmed cadherin-11 AJ formation between these human cancer cells and human fibroblasts ( Figure 1A & B ).
Cancer cells hijack fibroblast cell bodies for invasion through 3D matrices
Next, to observe the cell co-invasion capabilities of these cancer cells and fibroblasts, we developed a "matrigel dam" directional 3D cell invasion assay in which we can adjust the serum concentration or the matrigel dam width to control cell invasion speed ( Figure 1C ). We determined that 20% serum driving cell invasion through a 1 cm wide matrigel dam showed a significant invasion speed difference between fibroblasts and cancers during their individual invasion in this assay. Pure fibroblasts ( Figure   1D , middle panels) invaded much faster with much higher persistence than the pure cancer cells ( Figure   1D , right panels) under the same conditions ( Figure 1E , F & G). However, strikingly, when fibroblasts and cancer cells were mixed together (1:1 ratio), these cancer cells physically associated with the fibroblasts and they managed to invade faster and also as persistently as the fibroblasts in this assay ( Figure 1D , left panels, Figure 1E High magnification zoom-in confocal imaging with elevated offsets on the red fluorescence channel revealed that cancer cells physically stayed adhered to the fibroblasts and migrated back and forth on the fibroblast body with high dynamics when these fibroblasts invaded through the 3-D matrix ( Figure 1H & I, Video 4). We also observed that fibroblasts formed long and thin cell body protrusions at the invasion front to invade through the 3-D matrix and cancer cells remained physically adhered to these long and thin fibroblast protrusions throughout the co-invasion ( Figure 1I ). In such cancer cellfibroblast co-invasion, almost none of the cancer cells invaded without adhering to fibroblasts ( Figure   1H & I, Video 4). Multiphoton microscopy imaging of a large cell population of cancer cells and fibroblasts during their co-invasion through 3D matrices in another cell invasion assay also confirmed strong physical adhesions between the cancer cells and the fibroblasts during their co-invasion (Figure S1A &B).
To avoid the possible concerns of cells touching the glass surface beneath the matrigel dam during invasion, a possible mixed 2.5-D 33 and 3-D cell invasion ( Figure 1C ), we employed a full 3-D spheroid cell invasion assay ( Figure 2A ) 34 . Interestingly in such assays, pure cancer cells expressing cadherin-11 did not invade much out of the spheroids into the surrounding 3-D matrices. By contrast, we observed significant cell invasion in all the spheroids that were composed of pure fibroblasts ( Figure 2B , upper panels, and Figure 2C ). When these cancer cells were mixed with fibroblasts in a 1:1 ratio (total cell numbers were maintained the same in all spheroids), we again observed striking cancer cell invasion together with the fibroblasts. Further, the cell bodies of many cancer cells partially co-localize with the cell bodies of the leading fibroblasts ( Figure 2B , bottom panels and zoom panels), confirming a proximal physical contact between cancer cells and fibroblasts during their co-invasion, as previously observed in our live cell imaging ( Figure 1H & I, Video 4).
Next, we sought to confirm such cancer cell and fibroblast co-invasion at the single-cell level without forcing proximal physical contacts by mixing thousands of cells in high densities to begin with as in the previous two cell invasion assays. By employing a microfluidic cell invasion device that is able to limit flow to allow just a couple of cells to pass through a narrow tunnel filled with 3-D matrices ( Figure 2D ) 35 , we observed such "cell hijacking" between one single cancer cell and one single fibroblast. It is important to point out that both cells started their own invasion as two separated single cells without any contact and such "cell hijacking" happened at the first contact as soon as they touched each other ( Figure 2E & Video 5). Interestingly, when the cancer cell was caught by the fibroblast, the cancer cell body almost totally rounded up while the fibroblast still maintained its invasive cell shape in the 3-D matrices. This suggests the cancer cell gave up its self-invasion but took the "train" (fibroblast) to travel. Thus, it is reasonable to describe such co-invasion as the cancer cell "hijacking" the fibroblast, but not vice versa (Video 5).
Co-invasion by cancer cells hijacking fibroblasts is cadherin-11 dependent
As cadherin-11 AJs can form between these cancer cells and fibroblasts ( Figure 1A & B), we next sought to determine the role of cadherin-11 in regulating such cancer cells hijacking fibroblasts for coinvasion. First, we confirmed that cadherin-11 siRNA successfully downregulated cadherin-11 protein expression in these cells ( Figure S2A & B ). In the same 3-D spheroid cell invasion assay as described previously, we observed that cadherin-11 downregulation promoted cell dissemination in these breast cancer cells ( Figure 3A ) when they were cultured alone, suggesting that same cell adhesion suppresses invasion of these cancer cells. In contrast, cadherin-11 downregulation inhibited cell invasion in a culture of sole fibroblasts ( Figure 3B ). Interestingly, we observed totally opposite cell invasion behaviors by equivalently perturbing cadherin-11 in human cancer cells and human primary fibroblasts ( Figure 3A & B) , which is not a too big surprise for us according to our previous publications about the clear differences between cancer cells and normal fibroblasts 36 . Cell-to-cell adhesion forces in AJs and TJs (tight junctions) are usually defined as "frictions" during cell dissemination or cell invasion 37, 38 .
Hence, it is easy to understand that when cell-to-cell adhesion forces in AJs are weakened by cadherin-11 downregulation, cell dissemination increases in these breast cancer cells. However, our results in fibroblasts from the same spheroid assay suggest that the "cell-to-cell adhesion friction" theory is not enough to explain the phenomenon in fibroblasts. Interestingly, this finding is consistent with previous studies, involving several different 3-D assays which reported that cell invasion significantly decreases in fibroblasts with a cadherin-11 blockade by a cadherin-11-Fc fusion protein or in fibroblasts from cadherin-11-null mice 32, 39 . Also, according to our findings above in untransfected wildtype cells, cancer cells alone didn't invade much while fibroblasts alone did invade a lot in the 3-D spheroid assay, suggesting that fibroblasts do have a strong driving power for invasion but cancer cells don't in this case ( Figure 2B) . Thus, by integrating information from all these studies, we see that, in contrast to the effects of cadherin-11 friction forces in regulating cell invasion, there exists an unknown mechanism by which cadherin-11 actually promotes cell invasion in fibroblasts. But such a mechanism could be negligible or nonexistent in all the cancer cells that we have tested ( Figure S2C ).
Hence, based on these findings, we speculate that fibroblasts are more like the "driving wheel" in a car where cadherin cell-to-cell adhesion friction plays as the resistance force and the pulling force between each adjacent cell concurrently. Whilst in cancer cells, which are more like the "non-driving wheel" in a car, cadherin cell-to-cell adhesion friction most likely only plays as the resistance force because the cancer cells themselves don't have a potent power for invasion by themselves in the 3-D assay ( Figure 2B However, in fibroblast and cancer cell coculture, fibroblasts are able to transmit power to drive the cancer cells to invade ( Figure 2B coculture panel). Next, we started to perturb cadherin-11 in the coculture system by silencing cadherin-11 in cancer cells only, or in fibroblasts only, or in both concurrently. Results revealed that in all cadherin-11 silencing cases, the co-invasion of cancer cells hijacking fibroblasts was significantly de-coupled ( Figure 3C -F; Figure S3A -D). Interestingly, silencing cadherin-11 in just cancer cells significantly drove fibroblasts to invade farther in the 3D coculture system ( Figure 3C , second row), which further suggests that cadherin cell-to-cell adhesion friction in cancer cells plays as the resistance force. When such resistance force is reduced by cadherin-11 silencing in these cancer cells, the neighboring fibroblasts were freed and let go for invasion. Thus, all these results suggest that, in coculture, fibroblasts transmit power to drive cancer cell invasion and such power transmission (most likely as the force transmission by physical pulling) is cadherin-11 cell-to-cell adhesion dependent.
Cadherin-11 is specifically expressed in triple negative breast cancer cells (TNBCs) and its high expression is associated with poor clinical outcome in breast cancer patients.
Bioinformatics analysis based on the CCLE (Cancer Cell Line Encyclopedia) 40, 41 database reveals that cadherin-11 is highly expressed in a subset of triple negative breast cancer cells (TNBCs), but not non-TNBCs ( Figure 4A ).
Clinical data from The Pathology Atlas of The Human Protein Atlas database (www.proteinatlas.org) 42 shows high expression of cadherin-11 correlates with poor patient survival in 1,075 breast cancer patients ( Figure 4B ). Next, we analyzed the clinical data from the breast cancer mRNA gene chip dataset of the KM-plotter database (www.kmplot.com/analysis/) 43 . Interestingly, high expression of cadherin-11 doesn't correlate with poor patient survival either in 626 patients by using the Overall Survival (OS) analysis method ( Figure 4C ) or in 1,764 patients by using the Patient Relapse-Free Survival (RFS) analysis method ( Figure 4D ). Instead, high expression of cadherin-11 significantly (logrank P = 0.041) correlates with poor patient survival in 664 patients by using the Distant Metastasis Free Survival (DMFS) analysis method ( Figure 4E ). Such an interesting finding from the patient survival clinical data clearly positions the significant role of cadherin-11 in cancer metastasis, which links up with our findings of cancer hijacking fibroblasts for invasion in 3D ex vivo studies above
Next, we sought to analyze the correlation between high expression of cadherin-11 with patient survival in triple negative breast cancer patients by using the DMFS analysis method as in Figure 4E . However, due to the very limited number of triple negative breast cancer patient survival data, instead, we analyzed the correlation between high expression of cadherin-11 with ER negative breast cancer patient survival in 68 patients by using the DMFS analysis method. Results show high expression of cadherin-11 extremely (logrank P = 0.035) correlates with poor patient survival in these patients ( Figure 4F ). Such clinical data further validates our findings of high cadherin-11 expression particularly in triple negative breast cancers from the CCLE database analysis as above ( Figure 4A ).
Overall, all the clinical data from these two databases suggests high expression of cadherin-11 in cancer cells, so that they can readily hijack fibroblasts by such a cadherin-11-to-cadherin-11 homophilic adhesion at the molecular level, significantly drives cancer progression in human patients, particularly with high relevance to distant metastasis progression.
Cadherin-11 mediates fibroblasts regulated tumor homing, growth and local invasion in human triple negative breast cancer with human fibroblast co-implantation xenograft mouse models.
Optimal cadherin based adherens junction formation is achieved by one type of cadherin binds to the "same" type of cadherin on the other cell in trans 30, 31 . Previous studies on cadherin-11 mediated cancer growth and progression in xenograft mouse models were done by implanting human breast cancer cells (with "human" cadherin-11) into the mouse stroma 44, 45 . It needs to be pointed out that mouse stromal fibroblasts express "mouse" cadherin-11 but not "human" cadherin-11. Although such a mouse model can be used to test the cadherin-11 intracellular signaling changes in these cadherin-11 bearing cancer cells themselves supported by a "mouse" stromal microenvironment in vivo, it is not suitable for studying the effects of homophilic molecular adhesions of "human" cadherin-11 on the cancer cells to "human" cadherin-11 on the stromal fibroblasts, which actually happens in human.
To focus on homophilic "human" cadherin-11 to "human" cadherin-11 adhesions between cancer cells and stromal fibroblasts, we designed a human triple negative breast cancer with primary human fibroblast co-implantation xenograft mouse model, which is similar to previous in vivo mouse studies done by human cancer and human fibroblast co-implantations [46] [47] [48] . We found that co-implantation with primary human fibroblasts significantly promoted human cancer cell growth in NOD/SCID mice as visualized by weekly bioluminescence imaging of MDA-MB-231-luc cells, especially at early time points after implantation ( Figure 5A & B, note only MDA-MB-231-luc cells have bioluminescence but fibroblasts don't). Such a finding was not obvious at later time points possibly because later cancer growth was largely supported by the mouse stroma. Further, co-implantation with primary human fibroblasts significantly raised the successful rate of MDA-MB-231-luc xenograft growth in these mice ( Figure 5A , B & C, note those small tumors with bioluminescence below 1 × 10 8 photons/s at week 11).
As a control, implantation of primary human fibroblasts alone into NOD/SCID mice did not form any tumors (data not shown). Interestingly, in vivo bioluminescence imaging of MDA-MB-231-luc cells revealed that cancer cells with fibroblast co-implantation underwent more local invasion (measured as total tumor area) compared to cancer cells without fibroblast co-implantation ( Figure 5D ), consistent with the cell invasion findings in the ex vivo 3D spheroid assays. Tumor volume measurements further showed that tumors of MDA-MB-231-luc with fibroblast co-implantation grew much faster and larger than tumors of MDA-MB-231-luc sole implantation ( Figure 5E ). Such a finding was also observed in triple negative breast cancer patient derived cancer (ID: PDX5993) with or without primary human fibroblast co-implantation xenografts in NOG mice. ( Figure 5F ). Overall, these results confirm that coimplantation with primary human fibroblasts promote human cadherin-11 positive triple negative breast cancer cell homing, growth and local invasion in mouse in vivo.
Previous studies on cadherin-11 in cancer progression in vivo were performed mainly by perturbing cadherin-11 expression level in cancer cells only to determine how cadherin-11 regulates cancer cells themselves, including studies on cadherin-11 regulated intracellular signalings and cadherin-11-tocadherin-11 homophilic adhesions between the same type of cancer cells 44, 45 . To avoid the effects of perturbing cadherin-11 in altering cancer cells themselves and to focus on how the cadherin-11-tocadherin-11 adhesions between the two different types of cells regulate human cancer hijacking human stromal fibroblasts in vivo, we chose to perturb cadherin-11 only in primary human fibroblasts in our human triple negative breast cancer with primary human fibroblast co-implantation xenograft mouse model. We found that the reduction of cadherin-11 expression in primary human fibroblasts ( Figure 6A) significantly reduced the enhancement of MDA-MB-231-luc growth in vivo ( Figure 6B & C) as well as the whole tumor growth ( Figure 6D ). Overall, these results confirm that human cancer hijacking human stromal fibroblasts in vivo with enhanced cancer progression is cadherin-11-to-cadherin-11 adhesion dependent.
Overexpression of cadherin-11 in 4T1 mouse triple negative breast cancer cells to enhance their adhesion to mouse fibroblasts promotes tumor invasion, growth and distal metastasis.
Next, we sought to determine the in vivo effects of cadherin-11 overexpression in cancer cells with their enhanced adhesion to stromal fibroblasts. 4T1 murine cancer implantation in BALB/c mice is a widely used immunocompetent triple negative breast cancer implantation mouse model, which very closely mimics triple negative breast cancer progression in human 49, 50 . Interestingly, although 4T1 cells are very invasive breast cancer cells, they express high levels of epithelial E-cadherin with almost no expression of mesenchymal N-cadherin or cadherin-11 ( Figure S4A) 51 . Thus, we firstly made stable cadherin-11 overexpressing 4T1 cell lines and confirmed the overexpression levels by Real-Time qRT-PCR ( Figure 7A ). Next, in our established ex vivo 3D spheroid assay, we observed that unlike the human BT549 TNBC cell line that showed little invasion on its own ( Figure 2B ), 4T1 wildtype cells showed invasion which was not enhanced by cadherin-11 overexpression ( Figure 7B , upper panels, and Figure 7C ). Furthermore, addition of mouse NIH3T3 fibroblasts did not enhance the invasion of 4T1 wildtype cells ( Figure 7B & C) . NIH3T3 fibroblasts did enhance the invasion of cadherin-11 overexpressing 4T1 cells ( Figure 7B & C) . In vivo experiments of 4T1 implantation into the mammary pads of BALB/c mice determined that tumors of 4T1 cells with mouse cadherin-11 overexpression grew significantly faster than those of 4T1 wildtype cells ( Figure 7D ). This is not due to an increased proliferation rate ( Figure 7E ). Moreover, BALB/c mice carrying tumors of 4T1 cells with mouse cadherin-11 overexpression died much earlier than those carrying tumors of 4T1 wildtype cells ( Figure   7F ). Micro-MRI imaging detected large metastatic tumor lesions at multiple lymph nodes under the dorsal neck skin in BALB/c mice carrying tumors of 4T1 cells with mouse cadherin-11 overexpression at the left 4 th mammary pads. In comparison, Micro-MRI imaging failed to detect any metastatic tumor lesion in BALB/c mice carrying tumors of 4T1 wildtype cells ( Figure 7G ). Overall, all these results suggest that 4T1 TNBC cells with mouse cadherin-11 overexpression can hijack mouse fibroblasts to promote tumor homing, growth, progression and metastasis with much shorter mouse survival in vivo.
Overexpression of cadherin-11 in 4T1 mouse triple negative breast cancer cells with firefly luciferase prevents immune rejection in immunocompetent BALB/c mice in vivo.
Recent studies discovered that implantation of 4T1-luc cells into immunocompetent BALB/c mice induces immune rejection against the tumor implant by the mouse immune system through recognition of the firefly luciferase protein as a foreign antigen 52 . Such a phenomenon is also described on the product sheet of the commercial 4T1-luc cells (PerkinElmer Inc). Initially, we planned the experiments of implanting 4T1-luc cells into BALB/c mice to determine if we could achieve a mild immune rejection so that we were able to observe 4T1-luc cell activities in vivo by bioluminescence imaging. However, a very strong immune rejection against the implanted wildtype 4T1-luc cells was observed. Very unexpectedly, in comparison, a much milder immune rejection was observed in the 4T1-luc cells with stable mouse cadherin-11 overexpression ( Figure 8A , B & C). To further confirm such an interesting and unexpected finding, we repeated the in vivo mouse experiments with different batches of cells for implantation and results stayed very similar ( Figure S5A , B & C). This is not due to a proliferation rate change ( Figure 8D ). In comparison, such an immune rejection in immunocompetent BALB/c mice, which can be partially reversed by cadherin-11 overexpression, was not observed in immunodeficient NOD/SCID mice with the implantation of the same 4T1-luc cells ( Figure 8E , F & G). Again, similarly to 4T1 cells without luciferase in BALB/c mice ( Figure 7D-G) , the tumor progression of 4T1-luc cells with cadherin-11 overexpression was much faster than 4T1-luc wildtype cells in NOD/SCID mice ( Figure 8E, F & G) . Such an interesting finding suggests that by hijacking mouse stromal fibroblasts in vivo by mouse cadherin-11-to-cadherin-11 adhesions, 4T1-luc cells with stable mouse cadherin-11 overexpression are able to significantly escape from the immune surveillance of the mouse immune system recognizing the firefly luciferase as a foreign antigen, which significantly prevents in vivo immune rejection against such cancer implants.
Discussion
Our findings firstly suggest that EMT is the origin but may not be the direct cause for cancer progression in vivo. Current prevailing EMT theory suggests epithelial cells undergo EMT so as to acquire the mesenchymal cell characteristics of being able to migrate, invade and metastasize on their own 3 . For example, the two widely used human triple negative breast cancer cell lines, MDA-MB-231 and BT549, have been recognized as very migratory and invasive cancer cells 53 . But these findings were previously observed mostly on 2D in vitro cell culture or Boyden Chamber based transwell cell migration and invasion assays. With the much-improved 3D ex vivo spheroid assays, we have observed that these cells are not very invasive on their own comparing to when they are cocultured with fibroblasts. Meanwhile, the previous in vivo findings of MDA-MB-231 and BT549 cells being invasive and metastatic in vivo were observed without considering their ideal physical interactions with fibroblasts in vivo by xenografting these human cancer cells expressing human cadherins into mouse stroma full of mouse cadherins 44, 45 . The cadherin biology studies have suggested that optimal cadherinto-cadherin binding is achieved by "homophilic binding" between same types of cadherins not across species 31, 54 . Here we have determined that the "cadherin switch" from E-cadherin to cadherin-11 readily grants cancer cells the capability of hijacking fibroblasts, which significantly promotes cancer progression both in vitro and in vivo. Another example, the long-time deemed very aggressive 4T1 cells actually have only undergone partial EMT without cadherin switch. The only cadherin that 4T1 cells endogenously express is still E-cadherin but not any other mesenchymal cadherins ( Figure S4A) 51 , although they are already very migratory, invasive and aggressive both in vitro and in vivo 49 . But, when we overexpressed cadherin-11 in 4T1 cells, they became even more aggressive and metastatic in vivo with significantly shorting mouse survival. Thus, we hereby provide significant updates to the EMT theory that the whole process of EMT may not significantly promote cancer progression itself, but the cadherin switch of the EMT process that enhances the interaction between cancer cells and the stroma, such a post-EMT event, might be the direct cause for enhanced cancer progression in human.
Such cancer cell physical interactions with fibroblasts in such a short distance, the length of two extracellular regions of cadherin-11 proteins that are bound in trans 55, 56 , may play further roles in promoting cancer cell proliferation, differentiation, escape from immune surveillance (Figure 8) , drug resistance and immunotherapy resistance beyond the studies that we have performed here.
Our study further suggests that EMT is sufficient and MET may not be required for cancer homing.
Recent studies have observed the plasticity of EMT in vivo and suggest that the reverse process MET promotes cancer homing and outgrowth at metastatic sites 57 . Stable knockdown of PRRX1 or TWIST or both, two of the key EMT-TFs, induced cancer colonization and outgrowth in lung 7, 8 . These studies have suggested that a partial or even complete reverse of EMT by the MET process might be involved in cancer homing and outgrowth in metastatic sites and have raised controversies and debates on the EMT theory 3, 6 . In comparison, we have observed that simply overexpressing the mesenchymal cadherin-11 in 4T1 cells, who endogenously only express E-cadherin, to enhance their adhesions to stromal fibroblasts is sufficient to promote their growth in situ, progression, metastasis and outgrowth in metastatic sites, such as lymph nodes (Figure 7 ). Our study suggests that the cadherin-11 mediated cancer cell hijacking fibroblasts is enough to promote cancer homing and MET is not required in such cases.
EMT cancer cells may be way smarter than we ever thought. For the cell invasion research field, in addition to the current knowledge of cancer cell self-invasion, cancer cell following fibroblast-made matrix tunnel invasion 17, 18 , cancer cell coupling with macrophage invasion by an EGF/CSF1 paracrine signaling loop [58] [59] [60] , we have discovered a novel cancer cell invasion mechanism of cadherin-11 homophilic adhesion mediated cancer cell hijacking fibroblast invasion. Such cell "hijacking" is achieved by EMT cancer cells, especially triple negative breast cancer cells, expressing fibroblast specific protein cadherin-11 26, 32 . This finding might help untangle the puzzle of why cadherin-11 expressing cancer cells are always more metastatic in vivo 27, 44 . Further, our study reveals such an alternative invasion mode when cadherin-11 positive cancer cells are surrounded by fibroblasts. Instead of being trapped and constrained by these neighboring giant cells, cancer cells hijack them by cadherin-11 and go with them. Interestingly, EMT cancer cells can do sole invasion by themselves, but when they manage to adhere to fibroblasts by engaging the cadherin-11-to-cadherin-11 adhesions, they gave up their own mesenchymal invasion but rather take the fibroblast "train" for a co-invasion, which may significantly save tremendous energy that cancer cells have to spend in doing mesenchymal invasion on their own. Such a smart energy saving strategy may further let cancer cells spend their precious energy in other valuable activities such as homing, proliferation and inducing angiogenesis.
Lastly, previous studies have focused on the extracellular intercell signalings between the cancer cells and the stromal fibroblasts in the "Seed and Soil" theory of cancer metastasis and homing 10 . Our study suggests that cadherin-11 can be the key molecule that readily engages EMT cancer cells to the surrounding stroma for enhanced survival, local invasion, distal metastasis, escape from immune surveillance and much more.
MATERIALS AND METHODS
Cells and proteins
Primary human fibroblasts were isolated from synovial tissue 23, 32 or purchased from ATCC (Manassas, VA). These cells were used for experiments between passages 5 to 10. MDA-MB-231, BT549, 4T1, NIH3T3, 293T cells were all purchased from ATCC (Manassas, VA). All cells were cultured in DMEM, supplemented with 10% fetal bovine serum (FBS), L-glutamine, and penicillin/streptomycin. Fibroblast growth factor (FGF) was added for maintaining primary human fibroblasts. All cell culture reagents were obtained from Thermo Fisher Scientific (Carlsbad, CA).
Animal studies
All experiments in mice were performed in accordance with relevant institutional guidelines and regulations and were subject to a protocol approved by Department of Health, Hong Kong. NOD/SCID female mice and BALB/c female mice were purchased from the Laboratory Animal Services Centre, the Chinese University of Hong Kong. Animals were housed 4-6 per cage under a light-dark (12 h/12 h) cycle with ad libitum access to water and food. Mice were 6-8 weeks old at time of tumor implantation. Cells at the exponential phase of growth were harvested and suspended with a matrigel (1.5 mg/ml, Cultrex® BME, Trevigen, Gaithersburg, MD) and collagen (0.35 mg/ml, Corning® Collagen I, Corning, NY) mixture. Mice were injected with 200 µl of cell suspension containing 1×10 6 or 2×10 6 cells into the left fourth abdominal fat pad by injection at the base of the nipple 61 . During injection mice were kept under inhalation anesthesia induced by 3% (V/V) and maintained at 0.8 -1% (V/V) mixture of isoflurane/oxygen through facial masks. Bioluminescence of tumors was measured every week on an IVIS Lumina XR imaging system (Perkin Elmer, Waltham, MA) after intraperitoneal injection of Dluciferin (150 mg/kg, 200 µl). Images were capture every minute for continuous 15 mins and analyzed by the Living Image® software (Perkin Elmer, Waltham, MA, USA). Tumor growth was monitored by measuring tumor length (L) and width (W) using Vernier calipers weekly (NOD/SCID mice) or every 2-3 days (BALB/c mice). Tumor volume (V) was calculated as [V = (L × W 2 )/2].
PDX establishment
The human breast cancer tissues were obtained from patients with informed consent who had surgery within 3 hours at the Department of Breast Surgery, Fudan University Shanghai Cancer Center (Shanghai, China). Tumor fragments of 30 to 60 mm 3 in volume were subcutaneously implanted in 6week old NOG mice (CIEA, Japan) weighing from 18 to 25 grams.
Micro-MRI (Magnetic Resonance Imaging)
All images were acquired using a 3 Tesla integrated small animal PET/MR scanner (nanoScan, Mediso Medical Imaging Systems Ltd, Budapest, Hungary). Mice were anesthetized via inhalation of 5 % isoflurane/oxygen gas mixture and placed on a pre-warmed mouse bed in the prone position. Mice were maintained using 2% isoflurane/oxygen during the imaging acquisition periods and were tightly wrapped together with the bed using a paper tape to reduce respiratory motion artifacts. For tumor detection, scans were performed in the coronal plane using a respiratory triggered T2-weighted 2D fast spin echo sequence with the following parameters: TR/TE 4000/71.4 ms; slice thickness 0.9 mm; inplane matrix 336 × 224; in-plane resolution 0.27 × 0.27 mm2; five signal acquisition. The average acquisition time was approximately 12 min, depending on the respiration rate of the mice.
Plasmid, siRNA, and transfection
Mouse cadherin-11 expression plasmid was from Sino biological Inc. (Wayne, PA). pGL4.51[luc2/CMV/Neo] vector encoding the firefly luciferase reporter gene luc2 was from Promega (Madison, WI). All siRNAs and shRNAs were from Thermo Fisher Scientific (Carlsbad, CA) or Dharmacon (Lafayette, CO, USA). Lipofectamine™ LTX, Lipofectamine™ 2000, and Lipofectamine™ 3000 reagents (Invitrogen, Carlsbad, CA) were used for transfecting expression plasmids. Lipofectamine™ RNAiMAX reagent (Invitrogen, Carlsbad, CA) was used for siRNA transfection. Lentiviruses carrying shRNA with GFP reporter were generated in 293T cells by the Trans-Lentiviral shRNA Packaging System (Dharmacon, Lafayette, CO). Lentiviruses were then collected and transferred to infect shRNA targeting cells. Stable shRNA silencing cell clones were selected by relevant antibiotics followed by cell sorting by the FACSAria III cell sorter flow cytometer (BD Biosciences, San Jose, CA).
Quantitative real-time polymerase chain reaction
Total RNAs were extracted by the Aurum ™ Total RNA mini kit (Bio-Rad Laboratories Inc., Hercules, CA, USA) and subject to qRT-PCR assays by the Power SYBR® Green RNA-to-Ct™ 1-Step Kit (Thermo Fisher Scientific, Waltham, MA) to measure molecule expression levels. Expression level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as reference control. qRT-PCR primers were from Sino Biological (Wayne, PA) or Genetimes ExCell (Hong Kong). All qRT-PCR experiments were run on the ViiA™ 7 Real-Time PCR System (Life Technologies, Thermo Fisher Scientific, Waltham, MA)
Antibodies
Mouse anti-cadherin-11 (clone 3H10 and 23C6) antibody has been described previously 26 . Mouse anti-cadherin-11 (clone 16A) antibody was from Millipore (Billerica, MA). Mouse anti-cadherin-11 (clone 5B2H5), Alexa Fluor conjugated anti-mouse, anti-rat and anti-rabbit secondary antibodies and Alexa Fluor conjugated phalloidin were obtained from Invitrogen (Carlsbad, CA).
Microscopy
For immunofluorescence microscopy, cells were labeled with a primary antibody for 1 hour at room temperature or 16 hours at 4°C, followed by secondary antibody labeling for 1 hour, and then mounted on slides with FluorSave™ Reagent (Calbiochem, San Diego, CA). For confocal microscopy, images were captured on various confocal microscopes at the Brigham & Women's Hospital Confocal Microscopy Core Facility, the Analytical Imaging Facility of the Albert Einstein College of Medicine, the Nikon Imaging Center at Harvard Medical School, the Integrated Imaging Center at Johns Hopkins University, the Multiphoton Microscopy Core Facility at The MD Anderson Cancer Center and the Confocal Microscopy Core Facility at Hong Kong Baptist University. Confocal microscopy was performed by scanning multiple confocal layers along the z-axis. For live-cell imaging, cells were grown in 35 mm glass-bottomed Fluorodishes (World Precision Instruments, Sarasota, Florida), and then mounted onto the confocal microscope equipped with a heating chamber warmed to 37 °C and supplied with 10% CO2. Sections of confocal images were scanned along the cell z axis every 1 min. After imaging, 3-D stacks of images at each time point were projected into a 2D image. Image reconstruction and quantitative colocalization analyses were performed using MetaMorph imaging software version 7.6.1.0 (Universal Imaging, Chesterfield, PA), Leica LAS X software (Leica Microsystems GmbH, Wetzlar, Germany), Zeiss Zen microscope software (Carl Zeiss Microscopy GmbH, Jena, Germany), ImageJ software or Fiji software, etc.
3-D spheroid cell invasion assay and microfluidic devices
Cells were pre-labeled by using the Vybrant™ Multicolor Cell-Labeling Kit (DiO, DiI, DiD Solutions) (Invitrogen, Carlsbad, CA). Each spheroid was made by resuspending 8,000 cells in 15 µl media with 0.24% methyl cellulose (4,000 cpi, Sigma-Aldrich, St. Louis, MO) by the hanging drop method 34 . Each spheroid was then embedded in 400 µl extracellular matrix (ECM) with 6 mg/ml matrigel (Cultrex® BME, Trevigen, Gaithersburg, MD) and 1.4 mg/ml collagen (Corning® Collagen I, Corning, NY). After the ECM was solidified, 200 µl liquid media were placed on top to cover the ECM. The final serum concentration in all spheroid assay experiments was 6.7% except for the cytokine stimulation spheroid experiments, in which the final serum concentration was 1.3%. The 3-D spheroid made by this hanging drop method is like a 3-D pancake shape with long X-Y axes but a shorter Z axis, which is perfect for confocal imaging. Cell invasion was quantitated by the ratio of the protrusion area over the core area (Figure 2A ). The microfluidic devices were manufactured by following the method that was described previously 62 . Further details were described in Figure 2D .
Western blotting
Cells were lysed in buffer (1% Triton X-100, 50 mM HEPES pH 7.4, 150 mM NaCl, 5 mM EDTA, 5 mM EGTA, 20 mM NaF, 20 mM sodium pyrophosphate, 1 mM PMSF, 1 mM Na3VO4). Samples were then separated by SDS-PAGE gels, transferred to PVDF membrane, and visualized by chemiluminescence (Thermo Fisher Scientific, Rockford, IL). . Fibroblasts regulate tumor homing, growth and local invasion in triple negative breast cancer with fibroblast co-implantation xenograft mouse models. 1 × 10 6 of cancer cells with/without 1 × 10 6 of primary human fibroblast cells were implanted into the left fourth mammary fat pad of NOD/SCID (for MDA-MB-231, 5A-5E), or NOG (for PDX5993, 5F) mice. A. Comparison of bioluminescence intensity in NOD/SCID mice at 2 to 11 weeks after implantation between the MDA-MB-231-Luc cells only implantation group (MDA-luc only, blue) and the MDA-MB-231-Luc cells with primary human fibroblasts co-implantation group (MDA-luc w/Fibroblast, red). B. Representative in vivo bioluminescence images from (A) in the early stage (3 weeks, left panel) and the late stage (11 weeks, right panel) post implantation. C. Fibroblasts supported tumor formation at 11 weeks after implantation. Tumors with total bioluminescence above 1 × 10 8 photons/s were considered as successful growth. D. Fibroblasts stimulated tumor local invasion as quantified by the total area of the visualized bioluminescence from MDA-MB-231-luc cells in vivo with or without fibroblast coimplantation. E. Comparison of tumor volume in NOD/SCID mice at 2 to 11 weeks after implantation between the MDA-MB-231-Luc cells only implantation group and the MDA-MB-231-Luc cells with primary human fibroblasts co-implantation group. F. Comparison of tumor volume in NOG mice at 3 and 4 weeks after implantation of patient-derived triple negative breast cancer cell xenograft PDX5993 with or without primary human fibroblast co-implantation. Data were presented as mean ± SD. n=8 in (A-E). n=4 in (F). P values were determined by two-tailed Student's t tests (NS, not significant; *, 0.01 < p < 0.05; **, p < 0.01). Figure 6 . Silencing of cadherin-11 in primary human fibroblasts suppresses tumor progression in the triple negative breast cancer with fibroblast co-implantation xenograft mouse model. A. Primary human fibroblasts were transduced by GIPZ lentiviral CDH11 shRNA or non-silencing shRNA with a GFP reporter. Stable transductant cells were sorted out by FACS based on the GFP signal. Silencing of CDH11 in these cells was then quantified by RT-qPCR. B. Effect of CDH11 silencing in human fibroblasts on cancer cell growth in the cancer with fibroblast co-implantation xenograft mouse model. 1 × 10 6 of MDA-MB-231-luc cells mixed with 1 × 10 6 of stable non-silencing (blue) or CHD11 silencing (red) primary human fibroblasts were co-implanted into the left fourth mammary fat pad of NOD/SCID mice. The bioluminescence of the MDA-MB-231-Luc cells were measured every 2 weeks. C. Representative in vivo bioluminescence images from (B) at 14 weeks after cancer with fibroblast coimplantation. D. Comparison of tumor volume in mice co-implanted with MDA-MB-231-luc cells and non-silencing or CDH11 silencing primary human fibroblasts. Data were presented as mean ± SD (n=8). P values were determined by two-tailed Student's t tests (NS, not significant; *, 0.01 < p < 0.05). 
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